Literature DB >> 2186027

Sensitive, soluble chromogenic substrates for HIV-1 proteinase.

A D Richards1, L H Phylip, W G Farmerie, P E Scarborough, A Alvarez, B M Dunn, P H Hirel, J Konvalinka, P Strop, L Pavlickova.   

Abstract

By replacement of the P1' residue in a capsid/nucleocapsid cleavage site mimic with 4-NO2-phenylalanine (Nph), an excellent chromogenic substrate, Lys-Ala-Arg-Val-Leu*Nph-Glu-Ala-Met, for HIV-1 proteinase (kappa cat = 20 s-1, Km = 22 microM) has been prepared. Substitution of the Leu residue in P1 with norleucine, Met, Phe, or Tyr had minimal effects on the kinetic parameters (kappa cat and kappa cat/Km) determined at different pH values, whereas peptides containing Ile or Val in P1 were hydrolyzed extremely slowly. The spectrophotometric assay has been used to characterize the proteinase further with respect to pH dependence, ionic strength dependence, and the effect of competitive inhibitors of various types.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186027

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer.

Authors:  Y S Cheng; F H Yin; S Foundling; D Blomstrom; C A Kettner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

4.  Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.

Authors:  Milan Kozísek; Sandra Henke; Klára Grantz Sasková; Graeme Brendon Jacobs; Anita Schuch; Bernd Buchholz; Viktor Müller; Hans-Georg Kräusslich; Pavlína Rezácová; Jan Konvalinka; Jochen Bodem
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

5.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Development of activity assays for high-volume evaluation of human immunodeficiency virus (HIV) protease inhibitors in rat serum: results with ditekiren.

Authors:  K F Wilkinson; B D Rush; S K Sharma; D B Evans; M J Ruwart; J M Friis; M J Bohanon; P K Tomich
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

9.  Sensitive, hydrosoluble, macromolecular fluorogenic substrates for human immunodeficiency virus 1 proteinase.

Authors:  F Anjuère; M Monsigny; Y Lelièvre; R Mayer
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

10.  Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Martin Lepsík; Jirí Brynda; Pavlína Rezácová; Jana Václavíková; Ron M Kagan; Ladislav Machala; Jan Konvalinka
Journal:  Protein Sci       Date:  2008-06-17       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.